TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

TapImmune to Present at the 3rd Annual Sachs Bio Partnering & Investment Forum on February 23, 2015

Seattle, WA – February 20, 2015, TapImmune Inc. (OTCBB: TPIV), an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases, announced today Dr. Glynn Wilson, Chairman & CEO of TapImmune, will present an update on the progress of clinical programs on Monday, February 23, 2015 at 12:30 P.M . Dr. Wilson will present at the New York Academy of Sciences in New York, NY.

Dr. Wilson, Chairman & CEO of TapImmune, said, “We are pleased to be able to participate in Sachs Associates’ 3rd Annual Bio Partnering & Investment Forum. I look forward to sharing our Company’s story with the targeted audience this prestigious conference presents.”

About TapImmune Inc.

TapImmune Inc. is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company’s peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company’s technologies may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at markertherapeutics.com for details.

The 3rd Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma, and biotech to facilitate partnering and funding/investment. Sachs forums are recognized as the leading international stage for those interested in investing in the biotech and life science industry and are highly transactional. They draw together an exciting cross-section of early-stage/pre-IPO, late-stage, and public companies with leading investors, analysts, money managers, and pharmas.

Members of the investment community who are interested in meeting with management should contact Kirin M. Smith, PCG Advisory at (646)-863-6519 or ksmith@pcgadvisory.com.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

CONTACTS:

TapImmune Inc.,
Glynn Wilson, Ph.D.
Chairman & CEO
+1(866)-359-7541

PCG Advisory
Kirin M. Smith
Chief Operating Officer
+1(646)-863-6519

Sean Leous
Chief Communications Officer
+1(646) 863-8998

www.pcgadvisory.com

J. Streicher Capital, LLC
Robert Giordano
+1-917-327-3938